Education
About Us
Working with TipRanks
Follow Us
US Stem Cell (DE:BHV)
:BHV
Total Valuation
US Stem Cell has a market cap or net worth of €56.58K. The enterprise value is ―.
Market Cap€56.58K
Enterprise Value―
Share Statistics
US Stem Cell has 641,507,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding641,507,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
US Stem Cell’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee7.46K
Profits Per Employee-259.81K
Employee Count11
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of US Stem Cell is ―. US Stem Cell’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, US Stem Cell had revenue of 82.05K and earned -2.86M in profits. Earnings per share was 0.00.
Revenue82.05K
Gross Profit58.28K
Operating Income-1.72M
Pretax Income-2.86M
Net Income-2.86M
EBITDA-2.17M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -43.06K and capital expenditures 0.00, giving a free cash flow of -43.06K billion.
Operating Cash Flow-43.06K
Free Cash Flow-43.06K
Free Cash Flow per Share>-0.01
Dividends & Yields
US Stem Cell pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change0.00%
50-Day Moving Average0.02
200-Day Moving Average0.02
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
US Stem Cell upcoming earnings date is Aug 7, 2019, TBA Not Confirmed.
Last Earnings DateMay 7, 2019
Next Earnings DateAug 7, 2019
Ex-Dividend Date―
Financial Position
US Stem Cell as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, US Stem Cell has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
US Stem Cell EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
US Stem Cell has €0.00 in cash and marketable securities with $0.00 in debt, giving a net cash position of €0.00 billion.
Cash & Marketable Securities€0.00
Total Debt$0.00
Net Cash€0.00
Net Cash Per Share€0.00
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for US Stem Cell is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―